Enzerna Biosciences is a pre-clinical stage company.
Business Model:
Revenue: $0
Employees: 1-10
Address:
City: Raleigh
State: North Carolina
Zip:
Country: United States
Enzerna Biosciences solution is to destroy the toxic RNA molecule that is the root cause of nucleotide expansion disorders using Artificial Site-Specific RNA Endonucleases (ASREs). ASREs are rationally designed proteins, that when expressed in cells, can target the expanded repeat array and destroy the disease-causing RNA.
Contact Phone:
Contact Email:
Announced Date | Company | Transaction | Money Raised |
---|
Announced Date | Transaction | Number of Investors | Money Raised | Lead Investors | 11/2022 | Debt Financing | 1 | $250k |
North Carolina Biotechnology Center North Carolina Biotechnology Center |
---|
Announced Date | Name | Price |
---|
|
Revenue: 0 - 100000 Employees: Industry: Software |
Details
|
|
Revenue: 0 - 100000 Employees: 51 - 500 Industry: Education |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Blockchain |
Details
|
|
Revenue: 0 - 100000 Employees: 11 - 50 Industry: Industrial |
Details
|
|
Revenue: 0 - 100000 Employees: 1 - 10 Industry: Advertising |
Details
|